Global, Multicentre, Non Interventional Advagraf Conversion Registry in Kidney Transplant Patients (CHORUS)

October 29, 2024 updated by: Astellas Pharma Europe Ltd.

Global Multicentre Kidney Transplant Advagraf Conversion Registry. A Non-interventional Post-authorisation Study (PAS)

A study to evaluate changes over time in renal function from baseline (time of conversion) up until five years post conversion in kidney transplant patients converted from tacrolimus twice daily (BD) formulations to a once daily formulation as Advagraf.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

This is a multicenter long-term (up to five years post-conversion), non-interventional registry in kidney transplant patients who have been converted from tacrolimus BD to Advagraf. Centers that are providing medical care for kidney transplant patients who may convert patients from tacrolimus BD to Advagraf will be identified and requested to approach patients for consent to participate.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Observational

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
4430

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Australia
    • New South Wales
      • Camperdown, New South Wales, Australia, 2050
        • Site AU6107
      • Gosford, New South Wales, Australia, 2250
        • Site AU6106
      • New Lambton, New South Wales, Australia, 2305
        • Site AU6104
      • Westmead, New South Wales, Australia, 2145
        • Site AU6103
    • Queensland
      • Harvey Bay, Queensland, Australia, 4655
        • Site AU6111
    • South Australia
      • North Adelaide, South Australia, Australia, 5000
        • Site AU6108
    • Western Australia
      • Nedlands, Western Australia, Australia, 6009
        • Site AU6110
      • Perth, Western Australia, Australia, 6150
        • Site AU6105
  • Austria
    • Oberösterreich
      • Linz, Oberösterreich, Austria, 4020
        • Site AT4304
    • Steiermark
      • Graz, Steiermark, Austria, 8036
        • Site AT4301
    • Tirol
      • Innsbruck, Tirol, Austria, 6020
        • Site AT4302
      • Innsbruck, Tirol, Austria, 6020
        • Site AT4303
  • Belgium
    • Vlaams Brabant
      • Leuven, Vlaams Brabant, Belgium, 3000
        • Site BE3201
  • Canada
    • British Columbia
      • Vancouver, British Columbia, Canada, V6Z 1Y6
        • Site CA1001
  • Czechia
      • Olomouc, Czechia, 775 20
        • Site CZ4202
  • France
      • Paris, France, 75475
        • Site FR3323
    • Alpes-Maritimes
      • Nice, Alpes-Maritimes, France, 06000
        • Site FR3310
    • Alsace
      • Strasbourg, Alsace, France, 67091
        • Site FR3318
    • Bouches-du-Rhône
      • Marseille Cedex 5, Bouches-du-Rhône, France, 13385
        • Site FR3315
    • Calvados
      • Caen, Calvados, France, 14033
        • Site FR3303
    • Doubs
      • Besancon Cedex, Doubs, France, 25030
        • Site FR3306
    • Finistère
      • Brest, Finistère, France, 29200
        • Site FR3311
    • Gironde
      • Bordeaux, Gironde, France, 33076
        • Site FR3302
    • Haute-Garonne
      • Toulouse, Haute-Garonne, France, 31059
        • Site FR3313
    • Haute-Normandie
      • ROUEN cedex, Haute-Normandie, France, 76031
        • Site FR3307
    • Hautte-Vienne
      • Limoges, Hautte-Vienne, France, 91211
        • Site FR3321
    • Ille-et-Vilaine
      • Rennes Cedex, Ille-et-Vilaine, France, 35033
        • Site FR3317
    • Indre-et-Loire
      • Tours, Indre-et-Loire, France, 37044
        • Site FR3305
    • Loire
      • Saint-Etienne Cedex 2, Loire, France, 42055
        • Site FR3309
    • Loire-Atlantique
      • Nantes, Loire-Atlantique, France, 44093 CEDEX 1
        • Site FR3312
    • Maine-et-Loire
      • Angers, Maine-et-Loire, France, 49933
        • Site FR3314
    • Nord
      • Lille, Nord, France, 59037
        • Site FR3325
    • Picardie
      • Amiens Cedex 1, Picardie, France, 80054
        • Site FR3308
    • Puy-de-Dôme
      • Clermont Ferrand Cedex 1, Puy-de-Dôme, France, 63003
        • Site FR3319
    • Rhône-Alpes
      • Lyon Cedex 03, Rhône-Alpes, France, 69003
        • Site FR3324
    • Vienne
      • POITIERS cedex, Vienne, France, 86021
        • Site FR3322
    • Île-de-France
      • Creteil, Île-de-France, France, 94000
        • Site FR3301
      • Le Kremlin Bicetre Cedex, Île-de-France, France, 94275
        • Site FR3316
  • Germany
    • Baden-Württemberg
      • Mannheim, Baden-Württemberg, Germany, 68167
        • Site DE4902
    • Bayern
      • Wuerzburg, Bayern, Germany, 97080
        • Site DE4901
    • Niedersachsen
      • Hannover, Niedersachsen, Germany, 30625
        • Site DE4903
  • Greece
      • Athens, Greece, 10675
        • Site GR3002
      • Athens, Greece, 11528
        • Site GR3004
  • Hong Kong
      • Hong Kong, Hong Kong
        • Site HK8201
      • Hong Kong, Hong Kong
        • Site HK8521
  • Hungary
      • Budapest, Hungary, 1082
        • Site HU3602
    • Hajdú-Bihar
      • Debrecen, Hajdú-Bihar, Hungary, 4032
        • Site HU3601
  • Italy
      • Bari, Italy, 70124
        • Site IT3905
      • Bologna, Italy, 40138
        • Site IT3902
      • Bolzano, Italy, 39100
        • Site IT3914
      • Genova, Italy, 16132
        • Site IT3901
      • L'Aquila, Italy, 67100
        • Site IT3904
      • Novara, Italy, 28100
        • Site IT3911
      • Novara, Italy, 28100
        • Site IT3916
      • Padova, Italy, 35100
        • Site IT3910
      • Perugia, Italy, 06129
        • Site IT3909
      • Salerno, Italy, 84131
        • Site IT3912
      • Salerno, Italy, 84134
        • Site IT39013
      • Salerno, Italy, 84134
        • Site IT3913
      • Sassari, Italy, 07100
        • Site IT3908
      • Udine, Italy, 33100
        • Site IT3915
      • Venezia, Italy, 30031
        • Site IT3906
    • Campania
      • Napoli, Campania, Italy, 80131
        • Site IT3903
    • Veneto
      • Verona, Veneto, Italy, 37126
        • Site IT3907
  • Japan
      • Akita, Japan
        • Site JP8101
      • Niigata, Japan
        • Site JP8102
    • Aiti
      • Nagoya-shi, Aiti, Japan
        • Site JP8108
      • Toyoake, Aiti, Japan
        • Site JP8109
    • Hyôgo
      • Nishinomiya, Hyôgo, Japan
        • Site JP8110
      • Nishinomiya, Hyôgo, Japan
        • Site JP8111
    • Kanagawa
      • Kawasaki-shi, Kanagawa, Japan
        • Site JP8106
    • Tiba
      • Chiba, Tiba, Japan
        • Site JP8107
    • Tôkyô
      • Ota-ku, Tôkyô, Japan
        • Site JP8105
      • Shinjuku-Ku, Tôkyô, Japan
        • Site JP8104
  • Korea, Republic of
    • Busan Gwang'yeogsi [Pusan-Kwan
      • Busan, Busan Gwang'yeogsi [Pusan-Kwan, Korea, Republic of, 48775
        • Site KR8214
      • Busan, Busan Gwang'yeogsi [Pusan-Kwan, Korea, Republic of, 633-165
        • Site KR8205
      • Pusan, Busan Gwang'yeogsi [Pusan-Kwan, Korea, Republic of, 602-739
        • Site KR8203
    • Daegu Gwang'yeogsi
      • Daegu, Daegu Gwang'yeogsi, Korea, Republic of, 41931
        • Site KR8219
    • Daegu Gwang'yeogsi [Taegu-Kwan
      • Daegu, Daegu Gwang'yeogsi [Taegu-Kwan, Korea, Republic of, 700-721
        • Site KR8202
    • Daejeon Gwang'yeogsi [Taejon-K
      • Daejeon, Daejeon Gwang'yeogsi [Taejon-K, Korea, Republic of, 301-721
        • Site KR8207
    • Gwangju Gwang'yeogsi
      • Gwangju, Gwangju Gwang'yeogsi, Korea, Republic of, 61453
        • Site KR8212
    • Gyeonggido
      • Bucheon-city, Gyeonggido, Korea, Republic of, 14584
        • Site KR8216
    • Gyeonggido [Kyonggi-do]
      • Suwon, Gyeonggido [Kyonggi-do], Korea, Republic of, 16499
        • Site KR8218
    • Incheon Gwang'yeogsi [Inch'n-K
      • Incheon, Incheon Gwang'yeogsi [Inch'n-K, Korea, Republic of, 21565
        • Site KR8201
    • Seoul Teugbyeolsi [Seoul-T'ukp
      • Seoul, Seoul Teugbyeolsi [Seoul-T'ukp, Korea, Republic of, 06273
        • Site KR8211
      • Seoul, Seoul Teugbyeolsi [Seoul-T'ukp, Korea, Republic of, 06351
        • Site KR8210
      • Seoul, Seoul Teugbyeolsi [Seoul-T'ukp, Korea, Republic of, 110-744
        • Site KR8206
      • Seoul, Seoul Teugbyeolsi [Seoul-T'ukp, Korea, Republic of, 130-702
        • Site KR8209
      • Seoul, Seoul Teugbyeolsi [Seoul-T'ukp, Korea, Republic of, 134-701
        • Site KR8204
      • Seoul, Seoul Teugbyeolsi [Seoul-T'ukp, Korea, Republic of, 136-705
        • Site KR8208
      • Seoul, Seoul Teugbyeolsi [Seoul-T'ukp, Korea, Republic of, 8308
        • Site KR8213
    • Ulsan Gwang'yeogsi [Ulsan-Kwan
      • Ulsan, Ulsan Gwang'yeogsi [Ulsan-Kwan, Korea, Republic of, 44033
        • Site KR8215
  • Malaysia
    • Wilayah Persekutuan Kuala Lump
      • Kuala Lumpur, Wilayah Persekutuan Kuala Lump, Malaysia, 59100
        • Site MY6001
  • Netherlands
      • Groningen, Netherlands, 9713
        • Site NL3105
      • Utrecht, Netherlands, 3584
        • Site NL3101
    • Gelderland
      • Nijmegen, Gelderland, Netherlands, 6525
        • Site NL3103
    • Noord-Holland
      • Amsterdam, Noord-Holland, Netherlands, 1105
        • Site NL3104
  • Philippines
    • National Capital Region
      • Quezon City, National Capital Region, Philippines, 1102
        • Site PH6303
  • Poland
    • Lubelskie
      • Lublin, Lubelskie, Poland, 20-954
        • Site PL4808
    • Mazowieckie
      • Warszawa, Mazowieckie, Poland, 02-507
        • Site PL4801
    • Wielkopolskie
      • Poznan, Wielkopolskie, Poland, 60-479
        • Site PL4806
    • Zachodniopomorskie
      • Szczecin, Zachodniopomorskie, Poland, 70-111
        • Site PL4807
  • Portugal
      • Porto, Portugal, 4099-001
        • Site PT3511
  • Romania
      • Bucuresti, Romania, 022328
        • Site RO4001
      • Bucuresti, Romania, 022328
        • Site RO4002
      • Bucuresti, Romania, 022328
        • Site RO4003
    • Cluj
      • Cluj-Napoca;, Cluj, Romania, 400006
        • Site RO4004
  • Serbia
      • Belgrade, Serbia, 11000
        • Site SB3801
      • Belgrade, Serbia, 11000
        • Site SB3802
      • Novi Sad, Serbia, 21000
        • Site SB3803
    • Nišavski Okrug
      • Niš, Nišavski Okrug, Serbia, 18000
        • Site SB3804
  • Spain
      • Barcelona, Spain, 08025
        • Site ES3401
      • Barcelona, Spain, 08036
        • Site ES3403
    • A Coruña
      • Santiago de Compostela, A Coruña, Spain, 15706
        • Site ES3410
  • Taiwan
      • Tainan, Taiwan, 704
        • Site TW8861
    • Kaohsiung
      • Kaohsiung City, Kaohsiung, Taiwan, 82445
        • Site TW8862
    • Taichung Municipality
      • Taichung, Taichung Municipality, Taiwan, 40705
        • Site TW8863
  • Thailand
      • Khon Kaen, Thailand, 40002
        • Site TH6603
    • Krung Thep Maha Nakhon [Bangko
      • Bangkok, Krung Thep Maha Nakhon [Bangko, Thailand, 10330
        • Site TH6601
      • Bangkok, Krung Thep Maha Nakhon [Bangko, Thailand, 10400
        • Site TH6602
  • United Kingdom
      • Leeds, United Kingdom, LS9 7TF
        • Site GB4401
      • Liverpool, United Kingdom, L7 8XP
        • Site GB4402
      • London, United Kingdom, SW17 0QT
        • Site GB4408
    • Cambridgeshire
      • Peterborough, Cambridgeshire, United Kingdom, PE3 9GZ
        • Site GB4403
    • Devon
      • Exeter, Devon, United Kingdom, EX2 5DW
        • Site GB4405
    • Lancashire
      • Manchester, Lancashire, United Kingdom, M13 9WL
        • Site GB4406
    • Suffolk
      • Ipswich, Suffolk, United Kingdom, IP4 5PD
        • Site GB4407
  • Vietnam
    • Ha Noi, Thanh Pho
      • Ha Noi, Ha Noi, Thanh Pho, Vietnam, 10000
        • Site VN8401
    • Ho Chi Minh, Thanh Pho
      • Ho Chi Minh, Ho Chi Minh, Thanh Pho, Vietnam, 70000
        • Site VN8402

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Sampling Method

Probability Sample

Study Population

Kidney transplant recipients

Description

Inclusion Criteria:

  • Adult kidney transplant patients who are on tacrolimus BD and identified for conversion to Advagraf. Patients will only be approached about participating in the registry after their physician has made the decision to convert them to Advagraf. Patients previously treated with Advagraf and who have stopped for any reason will not be excluded from the registry provided that the physician has decided to convert.

Exclusion Criteria:

  • Patients currently taking Advagraf treatment

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Cohort
  • Time Perspectives: Prospective

Cohorts and Interventions

Group / Cohort

Group / Cohort

A group or subgroup of participants in an observational study that is assessed for biomedical or health outcomes.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Patients converted from tacrolimus BD to Advagraf
Oral
Drug: Tacrolimus
oral
Other Names:
  • Advagraf
  • FK506E
  • Astagraf XL
  • Prograf XL

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Change in renal function as measured by eGFR using the MDRD-4 formula
Time Frame: At transplantation, within 3 months after transplantation, up to 2 years pre-conversion and then every 6 months prior to conversion, at conversion (baseline), 12 months post-conversion and annually thereafter until EOS (up to 5 years post conversion)
Estimated Glomerular Filtration Rate (eGFR), Modification Diet in Renal Disease (MDRD-4), End of Study (EOS)
At transplantation, within 3 months after transplantation, up to 2 years pre-conversion and then every 6 months prior to conversion, at conversion (baseline), 12 months post-conversion and annually thereafter until EOS (up to 5 years post conversion)

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Change in renal function as measured by eGFR using the CKD-Epi formula
Time Frame: At transplantation, within 3 months after transplantation, up to 2 years pre-conversion and then every 6 months prior to conversion, at conversion (baseline), 12 months post-conversion and annually thereafter until EOS (up to 5 years post conversion)
Chronic Kidney Disease Epidemiology Collaboration (CKD-Epi)
At transplantation, within 3 months after transplantation, up to 2 years pre-conversion and then every 6 months prior to conversion, at conversion (baseline), 12 months post-conversion and annually thereafter until EOS (up to 5 years post conversion)
Overall patient survival
Time Frame: From transplantation to EOS (up to 5 years post conversion) or date of death from any cause
Patients who are lost to follow up or alive at EOS - or at time of analysis will be censored
From transplantation to EOS (up to 5 years post conversion) or date of death from any cause
Overall graft survival (time to graft loss)
Time Frame: From transplantation to date of graft loss
Defined as time from transplantation to graft loss. Graft loss is defined as re-transplantation, nephrectomy, death or as dialysis ongoing at end of study or at the time of discontinuation of the patient from the study. The date of graft loss is the earliest date of any of these events. In case of dialysis as reason for graft loss, the date of graft loss is the first day of the last ongoing dialysis period reported
From transplantation to date of graft loss
DSA status (de novo)
Time Frame: From transplantation to EOS (up to 5 years post conversion)
Donor Specific Antibody (DSA). Laboratory assessment performed where possible in accordance with standard of care
From transplantation to EOS (up to 5 years post conversion)
Incidence of BPAR episodes
Time Frame: From transplantation to EOS (up to 5 years post conversion)
Biopsy Proven Acute Rejection (BPAR). Severity by Banff classification (International standardisation of criteria for histological diagnosis of allograft rejection), treated and untreated, and steroid sensitive or resistant
From transplantation to EOS (up to 5 years post conversion)
Time to first incidence of BPAR episodes
Time Frame: From transplantation to EOS (up to 5 years post conversion)
Severity by Banff classification, treated and untreated, and steroid sensitive or resistant
From transplantation to EOS (up to 5 years post conversion)
Advagraf dose
Time Frame: From transplantation to EOS (up to 5 years post conversion)
From transplantation to EOS (up to 5 years post conversion)
Tacrolimus trough level
Time Frame: From transplantation to EOS (up to 5 years post conversion)
From transplantation to EOS (up to 5 years post conversion)
Current immunosuppressant regimen
Time Frame: From transplantation to EOS (up to 5 years post conversion)
Dose and formulation (additional to or instead of Advagraf)
From transplantation to EOS (up to 5 years post conversion)
Status of treatment with Advagraf
Time Frame: From transplantation to EOS (up to 5 years post conversion)
Patients who discontinued Advagraf treatment will be retained in the registry for data on long-term outcomes provided consent is not withdrawn. The reasons associated with the discontinuation will be recorded
From transplantation to EOS (up to 5 years post conversion)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Astellas Pharma Europe Ltd.

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Study Director: Medical Affairs Europe, Astellas Pharma Europe Ltd.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
March 5, 2015

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
September 30, 2022

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
September 30, 2022

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
September 18, 2015

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
September 18, 2015

First Posted (Estimated)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
September 22, 2015

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
October 31, 2024

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
October 29, 2024

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
October 1, 2024

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • 506-MA-1002

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

Access to anonymized individual participant level data will not be provided for this trial. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Kidney Transplantation

Clinical Trials on Tacrolimus

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings